$13.62 Million in Sales Expected for Antares Pharma, Inc. (ATRS) This Quarter
Brokerages expect Antares Pharma, Inc. (NASDAQ:ATRS) to post $13.62 million in sales for the current quarter, according to Zacks. Four analysts have provided estimates for Antares Pharma’s earnings. The highest sales estimate is $14.30 million and the lowest is $12.20 million. Antares Pharma posted sales of $13.48 million in the same quarter last year, which suggests a positive year over year growth rate of 1%. The firm is scheduled to report its next earnings results on Wednesday, November 8th.
According to Zacks, analysts expect that Antares Pharma will report full year sales of $13.62 million for the current year, with estimates ranging from $51.09 million to $56.70 million. For the next year, analysts anticipate that the business will report sales of $87.81 million per share, with estimates ranging from $78.10 million to $98.18 million. Zacks’ sales averages are a mean average based on a survey of analysts that cover Antares Pharma.
Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.01. The firm had revenue of $13.42 million for the quarter, compared to analyst estimates of $12.99 million. Antares Pharma had a negative return on equity of 41.37% and a negative net margin of 34.27%.
ATRS has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Antares Pharma in a research report on Friday, June 23rd. Chardan Capital began coverage on Antares Pharma in a research report on Friday, June 23rd. They issued a “buy” rating and a $5.00 target price on the stock. Vetr lowered Antares Pharma from a “strong-buy” rating to a “buy” rating and set a $3.47 price target for the company. in a research note on Monday, June 26th. Finally, Piper Jaffray Companies set a $4.00 price target on Antares Pharma and gave the company a “buy” rating in a report on Wednesday, July 26th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and two have given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $4.34.
COPYRIGHT VIOLATION NOTICE: “$13.62 Million in Sales Expected for Antares Pharma, Inc. (ATRS) This Quarter” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/10/03/13-62-million-in-sales-expected-for-antares-pharma-inc-atrs-this-quarter.html.
Shares of Antares Pharma (NASDAQ ATRS) opened at 3.43 on Tuesday. The company’s market cap is $536.48 million. Antares Pharma has a 52-week low of $1.41 and a 52-week high of $3.45. The company has a 50-day moving average price of $3.05 and a 200-day moving average price of $2.95.
Large investors have recently made changes to their positions in the stock. National Planning Corp grew its position in Antares Pharma by 11.5% in the second quarter. National Planning Corp now owns 58,233 shares of the specialty pharmaceutical company’s stock worth $186,000 after acquiring an additional 6,000 shares in the last quarter. KCG Holdings Inc. raised its position in Antares Pharma by 48.8% during the first quarter. KCG Holdings Inc. now owns 66,717 shares of the specialty pharmaceutical company’s stock valued at $189,000 after purchasing an additional 21,881 shares during the period. Schwab Charles Investment Management Inc. raised its position in Antares Pharma by 10.2% during the first quarter. Schwab Charles Investment Management Inc. now owns 289,093 shares of the specialty pharmaceutical company’s stock valued at $822,000 after purchasing an additional 26,847 shares during the period. Bank of New York Mellon Corp raised its position in Antares Pharma by 20.1% during the first quarter. Bank of New York Mellon Corp now owns 167,515 shares of the specialty pharmaceutical company’s stock valued at $476,000 after purchasing an additional 28,029 shares during the period. Finally, MML Investors Services LLC lifted its stake in shares of Antares Pharma by 228.2% in the 2nd quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock valued at $139,000 after purchasing an additional 30,000 shares during the last quarter. 36.77% of the stock is owned by hedge funds and other institutional investors.
About Antares Pharma
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related stocks with our FREE daily email newsletter.